Connection

Search Results to Kevan L. Hartshorn, MD

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Hartshorn, Kevan

PropertyValue
Research Expertise & Professional Interests I am a Medical Oncologist Boston University Medical Center with principle focus on solid tumors. I am Director of the Hematology/Oncology Fellowship program at Boston University School of Medicine for 18 years and also on-site PI for multicenter clinical trials of chemotherapy and targeted agents for various cancers. I participates in cooperative clinical trials groups (NSABP, SWOG, Alliance, and AIDs Clinical Trials group) and to a lesser extent in industry related clinical trials. I did my clinical training in Internal Medicine at Boston City Hospital and then did Fellowship training in Hematology/Oncology at Massachusetts General Hospital. After this I joined the Attending staff at Boston City Hospital and feel very devoted to the mission of Boston Medical Center (the name of the Hospital formed by the merger of Boston City Hospital and Boston University Hospital). This mission is to provide, “Exceptional Care Without Exception”. Boston Medical Center is the main safety net hospital for the city of Boston and prides itself on providing cutting edge care to patient’s regardless or economic or social status. The hospital cares for a large population of African American and immigrant patients and has developed a number of special services (e.g. care navigators) to under-served patients get the care they need. In addition to the above clinical research interests, I have a particular interest in Geriatric Oncology and shared in developing a clinical Fellowship in Geriatric Oncology here which has now been in existence for about 10 years. I have a long standing interest in health care disparities as well. I have mentored numerous Fellows, Medical Students, Residents and College and High School students over the years in clinical care, clinical research and basic research. In addition to my clinical interests have a laboratory research program related to innate immunology have had continuous NIH grant support for 30 years. Our research principally deals with innate immunity, which refers to immune responses that are hard-wired into the genome and provide a first line of protection against infection or transformed cells. Innate immune responses are sometimes also responsible for damaging inflammation. Defects or variants in innate immunity account for increased propensity for infections or harmful inflammation. As an example, people lacking one of the collectins found in blood are at greater risk for infection during neutropenia and have a greater risk for certain cancers. There is surprising complexity and specificity to innate immunity despite the fact that it provides protection even when a person has not been exposed to a specific infection. The main aspects of innate immunity we study include neutrophils and monocyte/macrophages, toll like receptors, and soluble immune defense proteins called collectins and defensins. We study how neutrophils and monocytes become activated in response to infectious organisms (viruses and bacteria), including studies of cell signaling, phagocytosis and oxidant production. We study how defensins and collectins kill bacteria or viruses and promote their uptake by neutrophils and monocytes. We have created or collaborate to create and test a variety of new recombinant versions of collectins and defensins, some of which have strongly increased antiviral or antibacterial activity. We also collaborate with members of the department of Biophysics in crystallographic studies of collectin structure in order to predict protein changes that might confer greater antimicrobial activity. We also collaborate in use of mouse models (e.g., mice in which collectin genes are deleted) to study the role of specific innate immune mediators in infection. A particular area of interest for us is the innate immune response to respiratory infection, especially influenza virus infection. Influenza virus and HIV (which we also study to some extent) are important examples of infections for which innate immunity is important since these viruses undergo continuous mutation thus evading adaptive immune responses (i.e., specific T and B cell responses).

One or more keywords matched the following items that are connected to Hartshorn, Kevan

Item TypeName
Concept Terminal Care
Concept Patient Selection
Concept Multiprotein Complexes
Concept Patient Preference
Academic Article Multimerization of surfactant protein D, but not its collagen domain, is required for antiviral and opsonic activities related to influenza virus.
Academic Article Randomized controlled trial of a video decision support tool for cardiopulmonary resuscitation decision making in advanced cancer.
Academic Article Update on the Management of Pancreatic Cancer in Older Adults.
Grant An Open Label, Randomized, Controlled, Phase III, Multicenter, Clinical Trial of PN401 with HighDose 5-Fluoraouracil (5FU) vs. Gemcitabine for Treatment of Patients with Advanced Pancreatic Cancer
Academic Article Clinical Care Manual for Care of the Adult Patient with HIV infection
Academic Article Clinical Care Manual for Care of the Adult Patient with HIV infection: Supplement
Academic Article HIV Infection: a Primary Care Manual (Libman H., Witzburg R, eds.)
Academic Article Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome.
Academic Article Neighborhood Characteristics and Colorectal Cancer Survivors'' Quality of Care.
Grant A Randomized, Double-blind, Phase II Study of RAD001 10 mg/d plus Best Supportive Care versus Placebeo plus Best Supportive Care in the Treatment of Patients with Advanced Pancreatic Neuroendocri
Grant A Phase II, Multi-center, Open-label Trial to Evaluate the Efficacy and Safety of DAVANAT in Combination with 5-Fluorouracil when Administered as First Line Chemotherapy in Patients Advanced Bili
Grant A randomized, double-blind, multi-center phase III study comparing everolimus (RAD001) plus best supportive care vs placebo, plus best best supportive care in patients with advanced gastric cance

Highlights
Search Criteria
  • Care
  • Complex
  • Patients